Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027
Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504
Triggers Milestone Closing of
“Dosing the first participant in our Phase 1 trial marks an important milestone as we advance EQ504, our differentiated, oral, colon-targeted AhR modulator, into clinical development,” said
The Phase 1 trial (NCT07869225), being conducted in
The MAD portion will also evaluate EQ504's pharmacodynamic activity through multiple gastrointestinal (GI) mucosal biopsies, including measurement of cytochrome P450 1A1 (CYP1A1) expression, a biomarker of AhR pathway activation. These assessments are designed to provide early clinical evidence of localized target engagement and biological activity in the GI tract, supporting EQ504's differentiated, colon-targeted approach. An optional food-effect cohort will examine whether food affects EQ504 exposure.
Milestone Closing of
At the Milestone Closing, investors are expected to purchase and the Company expects to issue and sell 14,957,260 shares of common stock at a purchase price of
The offer and sale of the foregoing securities were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any applicable state securities laws. Accordingly, the securities may not be reoffered or resold in
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product.
About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential”, “will”, “designed to” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for reporting data from a Phase 1 study of EQ504; the potential benefits of EQ504; the anticipated initiation of a placebo-controlled proof-of-concept study in patients with ulcerative colitis; the expected Milestone Closing for the additional $20 million tranche under Equillium’s 2025 equity private placement, including receipt of the Price Threshold Waiver; the expected use of proceeds from the private placement; and Equillium’s expectations that its financial position and cash runway will fund currently planned operations into 2029. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; risks involving the expected Milestone Closing, including the occurrence and anticipated time and the impact the sale will have on the Company’s stock price; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Source: Equillium, Inc.
